Publication | Open Access

VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA

Interesting TargetInfusional 5-FluorouracilPancreatic CancerMedicinePathologyOncologyRadiation OncologyAdvanced Pancreas CancerMolecular OncologyCancer Growth